Mr. Conrad Pinette

Mr. Conrad Pinette
Team: 
Board of Directors
Positions: 

Chairman of the Board

Conrad Pinette was born in Manitoba, relocated to British Columbia in 1950 and educated at Private Schools in British Columbia and a program at UBC. He completed four years of a five Program in Forestry and Business Administration at UBC before returning to Williams Lake, BC to manage Family Businesses. Mr. Pinette sold the Family Forest Products business to British Columbia Forest Products Limited in 1982 and continued in Senior Executive positions with BCFP and Fletcher Challenge Canada Limited until 1990. 

Mr. Pinette joined Lignum Limited, a private forest products company, in 1990 as President and Chief Operating Officer. When it was sold to Riverside Forest Products Limited in December 2004, he continueed as Executive Vice President of Riverside until it was acquired by Tolko Industries Ltd in October 2005. He assisted Tolko in the integration of Riverside and Tolko from October 2005 to December 2006. 

A professional Director for a number of Forest Industry Public Companies and Mining Industry Companies from 1985 through 2011, Mr. Pinette was also Chairman of Finning Inernational Inc. from 2005 to 2011.

He is currently a Director of Canfor Corporation, Canfor Pulp Inc., Cariboo Foundation and the VGH and UBC Prostate Advisory Board.

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

PCF BC

Ride to Live 2018 and 50-50 Draw: May 27

The West Coast Motorcycle Ride to Live, raising funds for Prostate Cancer Foundation BC, takes place on Sunday May 27, 2018 in Vancouver, Victoria & the Fraser Valley. Follow the links to join a ride or donate to a rider; or to buy a ticket for a 50/50 draw (BC residents only).

Employment

Work at the Vancouver Prostate Centre

Thursday, January 18, 2018

Discovery of a promising new medication to block "master key" of cancer growth

Dr. Chris Ong
Tuesday, February 20, 2018

Drs. Wyatt and Chi: ctDNA predicts resistance to AR-targeted therapy

VCHRI News article on study of ctDNA predicting resistance to AR-targeted therapy
DNA

Make A Difference

Help the Vancouver Prostate Centre fund research to find better treatments and a cure.